Intuitive Surgical, Inc. (ISRG) - Stock Analysis

Last updated: Sep 20, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Procedures grew 20% in Q3 and full-year procedure-growth guidance increased to 17%-17.5%. Shares gained 13.9% since September 8, supported by excellent margins, strong free cash flow, and da Vinci 5 demand.

Loading chart data...

Idea window: 9/21/2026 – 9/28/2026Sector: Healthcare

AI Analyst Overview

Last Price
$402.22
Market Cap
$138.95B
1D Return
+2.26%
YTD Return
-28.98%

Loading chart data...

Valuation Metrics

P/E
44.4
P/B
7.7
P/S
12.6
EV/EBITDA
30.8
Div Yield
—

Fundamental Analysis

8.0

Key Financial Insights: • Expanding Margins • Strong Liquidity • Share Dilution ISRG combines exceptional profitability, free cash flow, and debt-free liquidity with a premium valuation and dilution risks, favoring caution on entry price.

StrongFundamentals
PremiumValuation

Price Behavior

6.0

Key Price Behavior Insights: • Strong rebound • Resistance approaching • Support critical Support Level: $377.00–$383.00; stronger support $369.00–$371.00 Resistance Level: $397.72–$401.27 ISRG gained 5% last month and is nearing $397.72–$401.27 resistance; hold above $377–$383 support to sustain the rebound, while a breakout above resistance would be bullish.

Bullish
Cautious

Sentiment & News

7.0

Key News Insights: • R&D Expansion • Ion Momentum • Growth Risks Intuitive Surgical's innovation, Ion growth, and expanded EU indication support long-term upside, but slower procedures, China uncertainty, and valuation volatility remain near-term risks.

MedTechGrowth
ISRG
AI

AI Summary

7.0
Positive

ISRG remains a high-quality installed-base compounder, but at a premium valuation investors should require evidence that da Vinci 5, Ion, and international expansion can sustain growth despite slower U.S. procedures and lower instrument revenue per case from Extended Use Instruments.

PlatformGrowth
ValuationRisk
ProcedureGrowth
AI summary updated 1 days ago

Description

Intuitive Surgical develops, manufactures, and sells robotic and endoluminal systems and related instruments to support minimally invasive and diagnostic procedures worldwide. Its offerings include the da Vinci surgical platform and the Ion endoluminal system, complementary surgical tools and consumables, training programs, installation and maintenance services, and integrated software that provides operational and performance data to hospital programs. The company was founded in 1995 and is headquartered in Sunnyvale, California.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Sep 21Sep 28ISRGIntuitive Surgical, Inc.
Procedures grew 20% in Q3 and full-year procedure-growth guidance increased to 17%-17.5%. Shares gained 13.9% since September 8, supported by excellent margins, strong free cash flow, and da Vinci 5 demand.
Active+0.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.